$3.94
0.13% yesterday
Nasdaq, May 20, 03:57 pm CET
ISIN
US63009J1079
Symbol
NBTX
Sector
Industry

Nanobiotix - ADR Stock price

$3.83
+0.60 18.46% 1M
-0.24 5.86% 6M
+0.96 33.45% YTD
-3.40 47.03% 1Y
-1.93 33.51% 3Y
-9.67 71.63% 5Y
-9.67 71.63% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.12 2.92%
ISIN
US63009J1079
Symbol
NBTX
Sector
Industry

Key metrics

Market capitalization $180.44m
Enterprise Value $162.05m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.14
P/S ratio (TTM) P/S ratio 4.61
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $39.17m
EBIT (operating result TTM) EBIT $-30.67m
Free Cash Flow (TTM) Free Cash Flow $-9.45m
EPS (TTM) EPS $-0.80
P/E forward negative
P/S forward 8.95
EV/Sales forward 8.04
Short interest 0.01%
Show more

Is Nanobiotix - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Nanobiotix - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Nanobiotix - ADR forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Nanobiotix - ADR forecast:

Buy
90%
Hold
10%

Financial data from Nanobiotix - ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
39 39
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 22 22
21% 21%
56%
- Research and Development Expense 45 45
30% 30%
114%
-29 -29
46% 46%
-74%
- Depreciation and Amortization 1.69 1.69
8% 8%
4%
EBIT (Operating Income) EBIT -31 -31
45% 45%
-78%
Net Profit -36 -36
41% 41%
-92%

In millions USD.

Don't miss a Thing! We will send you all news about Nanobiotix - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nanobiotix - ADR Stock News

Neutral
GlobeNewsWire
9 days ago
PARIS and CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conference:
Neutral
GlobeNewsWire
16 days ago
Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancer Median Overall Survival of 23 months from date of diagnosis [95% CI; 17 months – not reached] Median Local Progression-Free Survival of 13.3 months from completion of radiation Notable findings observed in explorator...
Neutral
GlobeNewsWire
21 days ago
PARIS and CAMBRIDGE, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of full results from the completed dose escalation and d...
More Nanobiotix - ADR News

Company Profile

Nanobiotix SA engages in the development of nanoparticle-based technologies for the treatment of cancer. The company's technologies include NanoXray that improves the efficacy of radiation therapy against tumor cells. It also engages in the development of magnetic particles and laser activated nanoparticles for the treatment and diagnosis of cancer. The company was founded by Laurent Lévy and Abdel Kader Boussaha on March 4, 2003 and is headquartered in Paris, France.

Head office France
CEO Laurent Lévy
Employees 108
Founded 2003
Website www.nanobiotix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today